601.38
Medpace Holdings Inc stock is traded at $601.38, with a volume of 491.18K.
It is down -0.73% in the last 24 hours and up +17.28% over the past month.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
See More
Previous Close:
$605.82
Open:
$612.07
24h Volume:
491.18K
Relative Volume:
1.30
Market Cap:
$16.79B
Revenue:
$2.68B
Net Income/Loss:
$460.40M
P/E Ratio:
37.83
EPS:
15.8963
Net Cash Flow:
$711.00M
1W Performance:
+11.84%
1M Performance:
+17.28%
6M Performance:
+2.27%
1Y Performance:
+31.97%
Medpace Holdings Inc Stock (MEDP) Company Profile
Name
Medpace Holdings Inc
Sector
Industry
Phone
(513) 579-9911
Address
5375 MEDPACE WAY, CINCINNATI, OH
Compare MEDP vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MEDP
Medpace Holdings Inc
|
601.38 | 16.79B | 2.68B | 460.40M | 711.00M | 15.90 |
|
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
|
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-18-26 | Upgrade | TD Cowen | Sell → Hold |
| Feb-13-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-10-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-02-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Sep-03-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-29-25 | Downgrade | UBS | Neutral → Sell |
| Jul-23-25 | Downgrade | TD Cowen | Hold → Sell |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Apr-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-24-25 | Initiated | Leerink Partners | Market Perform |
| Oct-23-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-27-24 | Downgrade | UBS | Buy → Neutral |
| Sep-25-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-24 | Initiated | Truist | Hold |
| May-29-24 | Initiated | TD Cowen | Buy |
| May-28-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-24 | Initiated | Deutsche Bank | Hold |
| Feb-15-24 | Upgrade | UBS | Neutral → Buy |
| Oct-24-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-08-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-27-22 | Upgrade | UBS | Sell → Neutral |
| Sep-07-22 | Initiated | UBS | Sell |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Oct-02-20 | Upgrade | Truist | Hold → Buy |
| Jun-08-20 | Upgrade | Robert W. Baird | Underperform → Neutral |
| May-13-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Apr-30-20 | Upgrade | SunTrust | Sell → Hold |
| Apr-20-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Mar-17-20 | Downgrade | SunTrust | Hold → Sell |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Oct-31-18 | Upgrade | SunTrust | Hold → Buy |
| Sep-17-18 | Initiated | SunTrust | Hold |
| Jul-31-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-01-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-29-17 | Initiated | Raymond James | Mkt Perform |
| Jul-10-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
View All
Medpace Holdings Inc Stock (MEDP) Latest News
Medpace Stock: Cancellations Are Normalizing (NASDAQ:MEDP) - Seeking Alpha
Why Medpace Holdings (MEDP) Is Up 11.8% After Raising 2026 Guidance And Expanding Backlog - Yahoo Finance
Medpace Holdings Inc (MEDP) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Medpace Holdings Inc (MEDP) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
TD Cowen raises Medpace stock price target on bookings outlook By Investing.com - Investing.com South Africa
MEDPACE HOLDINGS INC : RBC RAISES TARGET PRICE TO $692 FROM $484 - Bitget
MEDPACE HOLDINGS INC : BMO RAISES TARGET PRICE TO $600 FROM $400 - Bitget
TD Cowen raises Medpace stock price target on bookings outlook - Investing.com
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
BMO raises Medpace stock price target to $600 on strong demand - Investing.com
Truist Raises Price Target on Medpace Holdings to $609 From $462, Keeps Hold Rating - marketscreener.com
RBC Raises Price Target on Medpace Holdings to $692 From $484, Keeps Outperform Rating - marketscreener.com
Medpace Holdings Inc (MEDP) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Medpace Holdings, Inc. (MEDP) Stock Forecasts - Yahoo Finance
Narrow-Moat Medpace's Stronger Bookings and Easing Cancellations Support Improved Near-Term Outlook - Morningstar
Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $508.55, Implies 4% Downside - TradingView
Medpace Holdings Inc (MEDP) Shares Surge 14.7% -- What GF Score of 93 Tells Investors - GuruFocus
Form 144 Medpace Holdings For: 23 July By Investing.com - Investing.com Nigeria
Medpace Holdings Inc (MEDP) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Record ... - Yahoo Finance
Medpace Holdings, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
Medpace Holdings, Inc. 2Q 2026: Revenue $707.33M, EPS $4.25— 10-Q Summary - TradingView
Medpace jumps 15%, order rebound eases fears - marketscreener.com
Medpace Holdings, Inc. Quarterly Earnings Report - Stock Titan
MEDP Stock Jumps On Earnings Beat And Raised 2026 Outlook - StocksToTrade
Medpace Holdings Inc (MEDP) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Medpace Holdings stock hits all-time high at 649.5 USD By Investing.com - Investing.com India
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook - Benzinga
Medpace (MEDP) Sees Significant Price Surge - GuruFocus
Medpace jumps 15% as order rebound eases fears - marketscreener.com
Medpace Holdings stock hits all-time high at 649.5 USD - Investing.com
Medpace (MEDP) Sees Significant Stock Surge - GuruFocus
Why Is Medpace (MEDP) Stock Soaring Today - TradingView
Earnings call transcript: Medpace tops Q2 2026 estimates, shares jump 18% - Investing.com Nigeria
Medpace: 'Buy' Financial Metric Improvements And Solid Q2 2026 Earnings (NASDAQ:MEDP) - Seeking Alpha
Earnings call transcript: Medpace tops Q2 2026 estimates, shares jump 18% By Investing.com - Investing.com South Africa
MEDP Earnings Review: Medpace Stock Soars on Bookings Beat - CMC Markets
Medpace Holdings Posts 17% Revenue Jump in Q2 2026, Beats on EPS - AlphaStreet
Medpace stock lifts CRO space after Q2 beat (MEDP:NASDAQ) - Seeking Alpha
Medpace Q2 Earnings Call Highlights - TradingView
Full Transcript: Medpace Hldgs Q2 2026 Earnings Call - Benzinga
Transcript : Medpace Holdings, Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
Medpace Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:MEDP) 2026-07-23 - Seeking Alpha
Medpace Holdings, Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Deutsche Bank Adjusts Medpace Price Target to $535 From $480, Maintains Hold Rating - marketscreener.com
S&P 500 Futures Fall In Premarket Trading; Medpace Holdings, Allegion Lead - Moomoo
Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $490.36, Implies 7% Downside - TradingView
Medpace Holdings, Inc. Reports Second Quarter 2026 Results - BioSpace
Medpace surges on earnings beat and raised guidance - Investing.com
Medpace (MEDP) Q3 2025 earnings summary - Quartr
MEDP: Medpace Holdings Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Medpace Holdings earnings beat by $0.27, revenue topped estimates - Investing.com Canada
Medpace Holdings Inc Stock (MEDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):